BIZARRE: 3 - You Need To See This

Cort G300 Glam and G300 Raw review

Cor-Tek might make a colossal number of guitars for other people, but its own brand, Cort, is gaining traction with sharply priced and very well-spec’d guitars such as this new G300 duo

Guitar World · May 22, 2023

Top 3 Biotech Stocks with Breakout Potential

The biotech industry is well-positioned to witness significant growth due to technological advancements and government spending. Moreover, given the sector’s defensive nature, biotech stocks Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY) might be solid buys in 2023. Read on.

StockNews.com · May 12, 2023

Cort KX700 EverTune review

“Siri, show me a modern S-style that is spec’d up for metal and has state-of-the-art hardware that keeps it in tune all of the time…”

Guitar World · Apr 24, 2023

4 Biotech Stocks to Add to Your Watchlist

The surging demand for viable drugs and vaccines, advanced therapies, and increasing investments in research and development make the biotech industry’s prospects bright. Thus, it could be wise to invest in fundamentally sound biotech stocks Amgen (AMGN), Vertex Pharmaceuticals (VRTX), BioNTech (BNTX), and Corcept Therapeutics (CORT).

StockNews.com · Apr 27, 2022

Corcept Therapeutics's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million in sales, a 2.8% increase since Q3.

Benzinga · Feb 16, 2022

Recap: Corcept Therapeutics Q4 Earnings

Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Feb 15, 2022